A double-blind, randomized, placebo-controlled, parallel study to evaluate the efficacy and safety of imidafenacin in patients with overactive bladder in Taiwan

Chuang Y.-C.Lin C.-C.PO-MING CHOWLien C.-S.Tsui K.-H.Chou C.-L.Lee H.-Y.Meng E.Kuo H.-C.2021-01-282021-01-2820211757-5664https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089827867&doi=10.1111%2fluts.12341&partnerID=40&md5=b9e9fca57f2f3b762a0094b2959ff2c1https://scholars.lib.ntu.edu.tw/handle/123456789/543783Objective: This study evaluated the efficacy and safety of imidafenacin 0.1 mg twice daily vs placebo for Taiwanese patients with overactive bladder (OAB) after a 12-week oral administration. Methods: This randomized, double-blind, placebo-controlled, twoadverse events; antimuscarinics; overactive bladder; pharmacotherapy[SDGs]SDG3imidafenacin; placebo; imidafenacin; imidazole derivative; urinary tract agent; adult; allergic conjunctivitis; Article; backache; constipation; controlled study; diarrhea; double blind procedure; drug efficacy; drug safety; drug screening; dry eye; femalA double-blind, randomized, placebo-controlled, parallel study to evaluate the efficacy and safety of imidafenacin in patients with overactive bladder in Taiwanjournal article10.1111/luts.12341328445992-s2.0-85089827867